Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of BG00012 in MS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Must be 18 to 55 years old, inclusive, at the time of informed consent.~2. Must have a confirmed diagnosis of relapsing-remitting MS according to McDonald criteria #1-4 (McDonald et al, 2001; Appendix 2).~3. Must have a baseline EDSS between 0.0 and 5.0, inclusive.~4. Must have experienced at least one relapse within the 12 months prior to randomization, with a prior cranial MRI demonstrating lesion(s) consistent with MS OR show evidence of Gd-enhancing lesions of the brain on an MRI performed within the 6 weeks.~5. Male and female subjects must be willing to take appropriate measures to prevent pregnancy.~Exclusion Criteria:~1. Primary progressive, secondary progressive, or progressive relapsing MS (as defined by Lublin and Reingold, 1996 \[Appendix 3\]).~2. History of malignancy.~3. History of severe allergic or anaphylactic reactions or known drug hypersensitivity.~4. History of abnormal laboratory results indicative of any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, renal, neurologic (other than MS), and/or other major disease.~5. History of human immunodeficiency virus (HIV).~6. History of drug or alcohol abuse (as defined by the Investigator) within the 2 years prior to randomization.~7. An MS relapse that has occurred within the 50 days prior to randomization AND/OR the subject has not stabilized from a previous relapse prior to randomization.~8. Body weight \>100 kg.~9. Positive for hepatitis C antibody and/or positive for hepatitis B surface antigen (HBsAg) at screening.~10. Any of the following abnormal blood tests at screening.~11. Any previous treatment with FUMADERM®, FAG-201, or BG00012.~12. A medication history that precludes entry into the study.~13. Female subjects who are currently pregnant or breast-feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).